Drug Combination Helps Alzheimer's Disease Patients in Pivotal Study
An experimental treatment in late-stage development hit a bullseye in a clinical trial with Alzheimer's disease patients. Axsome Therapeutics' (NASDAQ: AXSM) lead treatment candidate, AXS-05 significantly reduced symptoms of Alzheimer's disease agitation during the pivotal Advance-1 study.
Around 6 million Americans have Alzheimer's disease, and this figure is expected to reach 14 million by 2050. AXS-05 does not treat dementia directly, but it could alleviate symptoms of agitation that affect around 70% of Alzheimer's disease patients.
Image source: Getty Images.
Source Fool.com
